Shaping rheumatoid arthritis treatment: Clinical and demographic drivers of tsDMARDs versus bDMARDs prescription post-EMA pronouncement on JAK inhibitors. Insights from the AMBI-RA study

The 2023 EMA pronouncement on JAKis led to a shift in prescription patterns, promoting TNFis versus JAKis. The decline in JAKis prescription did not appear to be driven by EMA-identified baseline risk factors, suggesting a generalized, categorical change. This channeling may have compromised the appropriateness of treatment choices, diminishing effectiveness in the prospective cohort, particularly for first-line therapies.